Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers

European Neuropsychopharmacology

Volumn 18, Issue 12, 2008, Pages 882-887

  Angelucci, Francesco ^a   Ricci, Valerio ^b   Spalletta, Gianfranco ^a,c   Pomponi, Massimiliano ^b   Tonioni, Federico ^b   Caltagirone, Carlo ^a,c   Bria, Pietro ^b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Abusers; BDNF; Cannabis; NGF; Serum levels

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIS; NERVE GROWTH FACTOR; NEUROTROPHIN;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN NERVE CELL; CANNABIS ADDICTION; CLINICAL ARTICLE; DRUG ABUSE; FEMALE; HUMAN; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADOLESCENT; ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NERVE GROWTH FACTOR; YOUNG ADULT;

EID: 53649103819     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.07.008     Document Type: Article

References (63)

1. Acquas E., Pisanu A., Marrocu P., and Di Chiara G. Cannabinoid CB1b receptor agonists increase rat cortical and hippocampal actetylcholine release in vivo. Eur. J. Pharmacol. 401 (2000) 179-185
2. Angelucci F., Mathé A.A., and Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia (Review). Prog. Brain Res. 146 (2004) 151-165
3. Angelucci F., Brenè S., and Mathé A.A. BDNF in schizophrenia, depression and corresponding animal models (Review). Mol. Psychiatry 10 (2005) 345-352
4. Angelucci F., Ricci V., Pomponi M., Conte G., Mathé A.A., Attilio Tonali P., and Bria P. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J. Psychopharmacol. 21 (2007) 820-825
5. Angelucci F., Gruber S.H., El Khoury A., Tonali P.A., and Mathé A.A. Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Eur. Neuropsychopharmacol. 17 (2007) 756-762
6. Browne S.E., Lin L., Mattsson A., Georgievska B., and Isacson O. Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp. Neurol. 170 (2001) 36-47
7. Cabral G., and Dove Pettit D. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious diseases. J. Neuroimmunol. 83 (1998) 116-123
8. Cabral G.A., and Staab A. Effects on the immune system. In: Pertwee R. (Ed). Handbook of Experimental Pharmacology (2005), Springer-Verlag, Heidelberg 385-423
9. Carta G., Nava F., and Gessa G.L. Inhibition of hippocampal acetylcholine release after acute repeated delta9-tetrahydrocannabinol in rats. Brain Res. 809 (1998) 1-4
10. Chen J.P., Paredes W., Li J., Smith D., Lowinson J., and Gardner E.L. Delta 9-tetrahydrocannabinol produces naloxone blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102 (1990) 156-162
11. Chen J.P., Paredes W., Lowinson J.H., and Gardner E.L. Strainspecific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci. Lett. 129 (1991) 136-180
12. Connor B., and Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Brain Res. Rev. 27 (1998) 1-39
13. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., and Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398 (2006) 215-219
14. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacology 34 (1988) 605-613
15. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., and Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004) 1558-1572
16. Everitt B.J., Dickinson A., and Robbins T.W. The neuropsychological basis of addictive behaviour (Review). Brain Res. Brain Res. Rev. 36 (2001) 129-138
17. First M.B., Spietzer R.L., Gibbon M., and William J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders: Clinical Version: Administration Booklet. (1997), American Psychiatric Press, Washington, D.C.
18. French E.D. Delta9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226 (1997) 159-162
19. French E.D., Dillon K., and Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum substantia nigra. Neuroreport 8 (1997) 649-652
20. Friedman H., Klein T., and Specter S. Immunosuppression by marijuana components. In: Ader R., Felten D.L., and Cohen N. (Eds). Psychoneuroimmunology (1991), Academic, San Diego 931-953
21. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochemistry 232 (1995) 54-61
22. Gervasoni N., Aubry J.M., Bondolfi G., Osiek C., Schwald M., Bertschy G., and Karege F. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51 (2005) 234-238
23. Gessa G.L., Mascia M.S., Casu M., and Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur. J. Pharmacol. 327 (1997) R1-R2
24. Gessa G.L., Casu M.A., Carta G., and Mascia M.S. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex hippocampus reversal by SR141716A. Eur. J. Pharmacol. 355 (1998) 119-124
25. Gogtay N., Giedd J.N., Lusk L., Hayashi K.M., Greenstein D., Vaituzis A.C., Nugent III T.F., Herman D.H., Clasen L.S., Toga A.W., Rapoport J.L., and Thompson P.M. Dynamic mapping of human cortical development during childhood through early adulthood. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8174-8179
26. Grimm J.W., Lu L., Hayashi T., Hope B.T., Su T.P., and Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J. Neurosci. 23 (2003) 742-747
27. Ha D.H., Robertson R.T., Roshanaei M., and Weiss J.H. Enhanced survival and morphological features of basal forebrain cholinergic neurons in vitro: role of neurotrophins and other potential cortically derived cholinergic trophic factors. J. Comp. Neurol. 406 (1999) 156-170
28. Hamada A., Watanabe N., Ohtomo H., and Matsuda H. Nerve growth factor enhances survival and cytotoxic activity of human eosinophils. Brit. J. Haematology 93 (1996) 299-302
29. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959) 50-55
30. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
31. Hermann D., Sartorius A., Welzel H., Walter S., Skopp G., Ende G., and Mann K. Dorsolateral prefrontal cortex n-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol. Psychiatry 61 (2007) 1281-1289
32. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., and Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
33. Jockers-Scherübl M.C., Rentzsch J., Danker-Hopfe H., Radzei N., Schürer F., Bahri S., and Hellweg R. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neurosci. Lett. 400 3 (2006) 262-266
34. Johnston L.D., O'Malley P.M., Bachmann J.G., and Schulenberg J.E. Monitoring the future results on adolescent drug use 1975-2004: vol1. secondary school students (NIH Publication No 05-5727) Bethesda, MD.: NIDA (2006)
35. Kaminski N., Koh W.S., Yang K.H., Lee M., and Kessler F.K. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem. Pharmacol. 48 (1994) 1899-1908
36. Karege F., Schwald M., and Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 328 (2002) 261-264
37. Kastin A.J., Pan W., Maness L.M., and Banks W.A. Peptides crossing the blood-brain barrier: some unusual observations. Brain Res. 848 (1999) 96-100
38. Klein T.W., Newton C.A., Widen R., and Friedman H. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9- tetrahydrocannabinol on T lymphocyte and B lymphocyte mitogen responses. J. Immunopharmacol. 7 (1985) 451-466
39. Klein T.W., Kawakami Y., Newton C., and Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health 32 (1991) 465-477
40. Klein T., Newton C., and Friedman H. Cannabinoid receptor and immunity. Immunol. Today 19 (1998) 373-381
41. Klein T., Friedman H., and Specter S. Marijuana, immunity and infection. J. Neuroimmunol. 83 (1998) 102-115
42. Lad S.P., Neet K.E., and Mufson E.J. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 315-334
43. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Schott K., Langer H., and Gawaz M. Decreased brain-derived neurotrophic factor (BDNF)- and betathromboglobulin (beta-TG)-blood levels in Alzheimer's disease. Thromb. Haemost. 96 (2006) 102-103
44. Matochik J.A., Eldreth D.A., Cadet J.L., and Bolla K.I. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 77 (2005) 23-30
45. Melis M., Gessa G.L., and Diana M. Different mechanisms for dopaminergic excitation induced by opiates cannabinoids in the rat midbrain. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 24 (2000) 993-1006
46. Meredith G.E., Callen S., and Scheuer D.A. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res. 949 (2002) 218-227
47. Millaps C.L., Azrin R.L., and Mittemberg W. Neuropsychological effects of chronic cannabis use on the memory and intelligence of adolescents. J. Child Adolesc. Subst. Abuse 3 (1994) 47-55
48. Nava F., Carta G., Colombo G., and Gessa G.L. Effects of chronic delta9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in T-maze. Neuropharmacology 41 (2001) 392-399
49. Pan W., Banks W.A., Fasold M.B., Bluth J., and Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37 (1998) 1553-1561
50. Pistis M., Muntoni A.L., Pillolla G., and Gessa G.L. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur. J. Neurosci. 15 (2002) 1795-1802
51. Ranganathan M., and D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review (Review). Psychopharmacology (Berl) 188 (2006) 425-444
52. Schwartz R.H., Grunewald P.J., Klitzener M., and Fedio P. Short-term memory impairment in cannabis-dependent adolescents. Am. J. Dis. Child. 143 (1989) 1214-1219
53. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia (Review). Eur. Neuropsychopharmacol. 15 (2005) 319-329
54. Smith S.R., Terminelli C., and Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin- 10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293 (2000) 136-150
55. Solomon A., Aloe L., Pe'er J., Frucht-Pery J., Bonini S., Bonini S., and Levi-Schaffer F. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J. Allergy Clin. Immunology 102 (1998) 454-460
56. Sowell E.R., Trauner D.A., Gamst A., and Jernigan T.L. Development of cortical and subcortical brain structures in childhood and adolescence: a structural MRI study. Dev. Med. Child Neurol. 44 (2002) 4-16
57. Tal M., and Liberman R. Local injection of nerve growth factor (NGF) triggers degranulation of mast cells in rat paw. Neurosi. Lett. 221 (1997) 129-132
58. Tanda G., Pontieri F.E., and Di Chiara G. Cannabinoid heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism (comment). Science 276 (1997) 2048-2050
59. Tapert S.F., Baratta M.V., Abrantes A.M., and Brown S.A. Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J. Int. Neuropsychol. Soc. 8 (2002) 873-883
60. Thirthalli J., and Benegal V. Psychosis among substance users. Curr. Opin. Psychiatr. 19 (2006) 239-245
61. Thoenen H. Neurotrophins and neuronal plasticity. Science 270 (1995) 593-598
62. Yasutake C., Kuroda K., Yanagawa T., Okamura T., and Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatr. Clin. Neurosi. 256 (2006) 402-406
63. Zanardini R., Gazzoli A., Ventriglia M., Perez J., Bignotti S., Rossini P.M., Gennarelli M., and Bocchio-Chiavetto L. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J. Affect. Disord. 91 (2006) 83-86